SG11201811829QA - Ethynyl derivatives - Google Patents
Ethynyl derivativesInfo
- Publication number
- SG11201811829QA SG11201811829QA SG11201811829QA SG11201811829QA SG11201811829QA SG 11201811829Q A SG11201811829Q A SG 11201811829QA SG 11201811829Q A SG11201811829Q A SG 11201811829QA SG 11201811829Q A SG11201811829Q A SG 11201811829QA SG 11201811829Q A SG11201811829Q A SG 11201811829QA
- Authority
- SG
- Singapore
- Prior art keywords
- basel
- international
- grenzacherstrasse
- designated states
- roche
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16179837 | 2016-07-18 | ||
| PCT/EP2017/067495 WO2018015235A1 (en) | 2016-07-18 | 2017-07-12 | Ethynyl derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811829QA true SG11201811829QA (en) | 2019-02-27 |
Family
ID=56418435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811829QA SG11201811829QA (en) | 2016-07-18 | 2017-07-12 | Ethynyl derivatives |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US20190144458A1 (es) |
| EP (1) | EP3484889B1 (es) |
| JP (1) | JP6936305B2 (es) |
| KR (1) | KR20190026805A (es) |
| CN (1) | CN109476671B (es) |
| AR (1) | AR109075A1 (es) |
| AU (1) | AU2017299083B2 (es) |
| BR (1) | BR112019000314A2 (es) |
| CA (1) | CA3030788A1 (es) |
| CL (1) | CL2019000045A1 (es) |
| CO (1) | CO2018013824A2 (es) |
| CR (1) | CR20190014A (es) |
| DK (1) | DK3484889T3 (es) |
| ES (1) | ES2826389T3 (es) |
| HR (1) | HRP20201615T1 (es) |
| HU (1) | HUE051006T2 (es) |
| IL (1) | IL263884A (es) |
| LT (1) | LT3484889T (es) |
| MA (1) | MA45665B1 (es) |
| MX (1) | MX2019000442A (es) |
| PE (1) | PE20190382A1 (es) |
| PH (1) | PH12019500119A1 (es) |
| PL (1) | PL3484889T3 (es) |
| PT (1) | PT3484889T (es) |
| RS (1) | RS60908B1 (es) |
| RU (1) | RU2745068C2 (es) |
| SG (1) | SG11201811829QA (es) |
| SI (1) | SI3484889T1 (es) |
| TW (1) | TWI729169B (es) |
| WO (1) | WO2018015235A1 (es) |
| ZA (1) | ZA201900113B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6761821B2 (ja) | 2015-07-15 | 2020-09-30 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 代謝性グルタミン酸受容体モジュレーターとしてのエチニル誘導体 |
| CN110183456A (zh) * | 2019-07-11 | 2019-08-30 | 河南师范大学 | 一种2-芳基吲唑琥珀酰亚胺螺环化合物的合成方法 |
| US11515154B2 (en) * | 2020-10-27 | 2022-11-29 | Applied Materials, Inc. | Selective deposition of a passivation film |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004050039A2 (en) * | 2002-12-04 | 2004-06-17 | Merck & Co., Inc. | Spirocyclic ureas, compositions containing such compounds and methods of use |
| RU2478639C2 (ru) | 2005-05-24 | 2013-04-10 | Лаборатуар Сероно С.А. | Трициклические спиро-производные в качестве модуляторов crth2 |
| WO2008027466A1 (en) | 2006-08-31 | 2008-03-06 | Schering Corporation | Hydantoin derivatives useful as antibacterial agents |
| NZ581817A (en) | 2007-06-03 | 2012-05-25 | Univ Vanderbilt | Benzamide mglur5 positive allosteric modulators and methods of making and using same |
| CA2773038A1 (en) | 2009-09-04 | 2011-03-10 | P. Jeffrey Conn | Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US8389536B2 (en) | 2009-10-27 | 2013-03-05 | Hoffmann-La Roche Inc. | Positive allosteric modulators (PAM) |
| US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US8586581B2 (en) * | 2009-12-17 | 2013-11-19 | Hoffmann-La Roche Inc | Ethynyl compounds useful for treatment of CNS disorders |
| US8420661B2 (en) | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| US8772300B2 (en) | 2011-04-19 | 2014-07-08 | Hoffmann-La Roche Inc. | Phenyl or pyridinyl-ethynyl derivatives |
| KR101554803B1 (ko) | 2011-04-26 | 2015-09-21 | 에프. 호프만-라 로슈 아게 | Mglur5의 양성 알로스테릭 조절체로서 에틴일 유도체 |
| US10533000B2 (en) | 2011-05-26 | 2020-01-14 | Sunovion Pharmaceuticals, Inc. | Metabotrophic glutamate receptor 5 modulators and methods of use thereof |
| PT2729448E (pt) * | 2011-07-06 | 2015-12-02 | Gilead Sciences Inc | Compostos para o tratamento de vih |
| US20130123254A1 (en) | 2011-09-30 | 2013-05-16 | Barbara Biemans | Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification |
| UA110862C2 (uk) | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5 |
| CA2879489A1 (en) | 2012-10-18 | 2014-04-24 | F.Hoffmann-La Roche Ag | Ethynyl derivatives as modulators of mglur5 receptor activity |
| KR101656634B1 (ko) | 2012-10-18 | 2016-09-09 | 에프. 호프만-라 로슈 아게 | mGluR5 수용체 활성의 조절제로서 에틴일 유도체 |
| WO2014124560A1 (en) | 2013-02-18 | 2014-08-21 | Hua Medicine (Shanghai) Ltd. | Mglur regulators |
| UY35400A (es) | 2013-03-15 | 2014-10-31 | Novartis Ag | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| MA38885B1 (fr) * | 2013-09-25 | 2018-11-30 | Hoffmann La Roche | Dérivés d'éthynyle modulateurs allosteriques positifs (pam) du recepteur metabotropique du glutamate 4 (mglu4) |
| TWI649310B (zh) | 2014-01-10 | 2019-02-01 | 赫孚孟拉羅股份公司 | 乙炔基衍生物 |
| CN104860941B (zh) | 2014-02-25 | 2017-03-22 | 上海海雁医药科技有限公司 | 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 |
| PL3110802T3 (pl) * | 2014-02-25 | 2019-03-29 | F. Hoffmann-La Roche Ag | Pochodne etynylowe |
| JP6539749B2 (ja) | 2015-03-19 | 2019-07-03 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ｍＧｌｕＲ４のモジュレーターとしての３−（４−エチニルフェニル）ヘキサヒドロピリミジン−２，４−ジオン誘導体 |
| JP6761821B2 (ja) * | 2015-07-15 | 2020-09-30 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 代謝性グルタミン酸受容体モジュレーターとしてのエチニル誘導体 |
| US10391998B2 (en) | 2016-11-16 | 2019-08-27 | Ford Global Technologies, Llc | Vehicle systems and methods for reducing electrified vehicle noise, vibration, and harshness |
-
2017
- 2017-07-12 SG SG11201811829QA patent/SG11201811829QA/en unknown
- 2017-07-12 CR CR20190014A patent/CR20190014A/es unknown
- 2017-07-12 EP EP17742971.9A patent/EP3484889B1/en active Active
- 2017-07-12 RU RU2019102757A patent/RU2745068C2/ru active
- 2017-07-12 BR BR112019000314-2A patent/BR112019000314A2/pt not_active IP Right Cessation
- 2017-07-12 PE PE2018003348A patent/PE20190382A1/es unknown
- 2017-07-12 HU HUE17742971A patent/HUE051006T2/hu unknown
- 2017-07-12 MX MX2019000442A patent/MX2019000442A/es active IP Right Grant
- 2017-07-12 LT LTEP17742971.9T patent/LT3484889T/lt unknown
- 2017-07-12 DK DK17742971.9T patent/DK3484889T3/da active
- 2017-07-12 MA MA45665A patent/MA45665B1/fr unknown
- 2017-07-12 KR KR1020197003025A patent/KR20190026805A/ko active IP Right Grant
- 2017-07-12 JP JP2019502162A patent/JP6936305B2/ja active Active
- 2017-07-12 ES ES17742971T patent/ES2826389T3/es active Active
- 2017-07-12 RS RS20201217A patent/RS60908B1/sr unknown
- 2017-07-12 WO PCT/EP2017/067495 patent/WO2018015235A1/en unknown
- 2017-07-12 CN CN201780044455.5A patent/CN109476671B/zh active Active
- 2017-07-12 CA CA3030788A patent/CA3030788A1/en not_active Abandoned
- 2017-07-12 SI SI201730468T patent/SI3484889T1/sl unknown
- 2017-07-12 PT PT177429719T patent/PT3484889T/pt unknown
- 2017-07-12 PL PL17742971T patent/PL3484889T3/pl unknown
- 2017-07-12 AU AU2017299083A patent/AU2017299083B2/en not_active Ceased
- 2017-07-17 TW TW106123741A patent/TWI729169B/zh not_active IP Right Cessation
- 2017-07-17 AR ARP170101987A patent/AR109075A1/es unknown
-
2018
- 2018-12-19 CO CONC2018/0013824A patent/CO2018013824A2/es unknown
- 2018-12-20 IL IL263884A patent/IL263884A/en active IP Right Grant
-
2019
- 2019-01-07 CL CL2019000045A patent/CL2019000045A1/es unknown
- 2019-01-08 ZA ZA2019/00113A patent/ZA201900113B/en unknown
- 2019-01-16 PH PH12019500119A patent/PH12019500119A1/en unknown
- 2019-01-17 US US16/250,278 patent/US20190144458A1/en not_active Abandoned
-
2020
- 2020-05-01 US US16/865,233 patent/US11242349B2/en active Active
- 2020-10-08 HR HRP20201615TT patent/HRP20201615T1/hr unknown
-
2022
- 2022-01-04 US US17/568,530 patent/US20220127275A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808582RA (en) | Pyrrolotriazine compounds as tam inhibitors | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201805595TA (en) | Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
| SG11201407662WA (en) | Process for the preparation of treprostinil and derivatives thereof | |
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| SG11201408261UA (en) | Syringe | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201804672QA (en) | Systems and methods for production of low oxygen content silicon | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201807516UA (en) | 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier |